-
1 Comment
Orthocell Limited is currently in a long term uptrend where the price is trading 18.8% above its 200 day moving average.
From a valuation standpoint, the stock is 57.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 109.7.
Orthocell Limited's total revenue rose by 57.7% to $637K since the same quarter in the previous year.
Its net income has dropped by 110.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 37.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Orthocell Limited gets an overall score of 4/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
Sector | Healthcare |
Industry | Biotechnology |
ISIN | AU000000OCC6 |
Market Cap | 385M |
---|---|
PE Ratio | None |
Target Price | 0.55 |
Beta | 0.27 |
Dividend Yield | None |
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OCC.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025